101 related articles for article (PubMed ID: 18184634)
1. Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
McMahon RP; Kelly DL; Boggs DL; Li L; Hu Q; Davis JM; Carpenter WT
Schizophr Bull; 2008 Mar; 34(2):292-301. PubMed ID: 18184634
[TBL] [Abstract][Full Text] [Related]
2. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia.
Levine SZ; Goldberg Y; Samara M; Davis JM; Leucht S
Schizophr Res; 2015 May; 164(1-3):122-6. PubMed ID: 25790904
[TBL] [Abstract][Full Text] [Related]
3. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
4. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
5. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
6. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
David SR; Taylor CC; Kinon BJ; Breier A
Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
[TBL] [Abstract][Full Text] [Related]
7. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
8. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Ascher-Svanum H; Stensland MD; Kinon BJ; Tollefson GD
J Psychopharmacol; 2005 Nov; 19(6 Suppl):110-7. PubMed ID: 16280344
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.
Srisurapanont M; Maneeton N
J Med Assoc Thai; 1999 Apr; 82(4):341-6. PubMed ID: 10410494
[TBL] [Abstract][Full Text] [Related]
10. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Keefe RS; Young CA; Rock SL; Purdon SE; Gold JM; Breier A;
Schizophr Res; 2006 Jan; 81(1):1-15. PubMed ID: 16202565
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.
Jeste DV; Dolder CR; Nayak GV; Salzman C
Harv Rev Psychiatry; 2005; 13(6):340-51. PubMed ID: 16373328
[TBL] [Abstract][Full Text] [Related]
13. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
Mozes T; Ebert T; Michal SE; Spivak B; Weizman A
J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):393-403. PubMed ID: 16958565
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
15. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
16. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
[TBL] [Abstract][Full Text] [Related]
17. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotics for the treatment of delirious elders.
Ozbolt LB; Paniagua MA; Kaiser RM
J Am Med Dir Assoc; 2008 Jan; 9(1):18-28. PubMed ID: 18187109
[TBL] [Abstract][Full Text] [Related]
19. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?
Leucht S; Engel RR; Bäuml J; Davis JM
Schizophr Bull; 2007 Jan; 33(1):183-91. PubMed ID: 16905632
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Volavka J; Nolan KA; Kline L; Czobor P; Citrome L; Sheitman B; Lindenmayer JP; McEvoy J; Lieberman JA
Schizophr Res; 2005 Jul; 76(1):127-9. PubMed ID: 15927808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
